STRO:NSD-Sutro Biopharma Inc.

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing Price

USD 11.37

Change

-0.05 (-0.44)%

Market Cap

USD 0.26B

Volume

6.56K

Average Target Price

USD 19.33 (+70.04%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
SHPG Shire plc

N/A

USD 54.84B
VRTX Vertex Pharmaceuticals Incorpo..

-0.21 (-0.12%)

USD 45.12B
REGN Regeneron Pharmaceuticals Inc.

+0.17 (+0.06%)

USD 32.71B
ALXN Alexion Pharmaceuticals Inc.

-0.22 (-0.18%)

USD 27.54B
INCY Incyte Corporation

-1.51 (-1.86%)

USD 17.13B
BMRN BioMarin Pharmaceutical Inc.

-1.62 (-1.93%)

USD 14.75B
SRPT Sarepta Therapeutics Inc.

-3.66 (-2.33%)

USD 11.36B
BIVV Bioverativ Inc.

N/A

USD 11.36B
ARRY Array BioPharma Inc.

-0.05 (-0.11%)

USD 10.34B
KITE Kite Pharma Inc.

N/A

USD 10.31B

ETFs Containing STRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 26.05% 66% D 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.05% 66% D 74% C
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.26B 54% F 47% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -0.45 17% F 57% F
Price/Book Ratio -1.84 93% A 96% A
Price / Cash Flow Ratio 7.15 3% F 12% F
Price/Free Cash Flow Ratio 12.78 5% F 33% F
Management Effectiveness  
Return on Equity 1,340.51% 99% A+ 99% A+
Return on Invested Capital -503.52% 3% F 1% F
Return on Assets -24.37% 76% C 24% F
Debt to Equity Ratio 0.25% 84% B 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Negative Book Value

The company has negative book value.